A Druggable Rheostat for Ewing Sarcoma?

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The posterior HOXD enhancer is an EWSR1::FLI1-dependent regulator of HOXD13 expression in Ewing sarcoma. HOXD13 expression promotes a mesenchymal cell state. Through antagonistic transcriptional programs, EWSR1::FLI1 and HOXD13 serve as master regulators of Ewing cell plasticity. Targeting Ewing cells as they exist in/transition between mesenchymal states is a priority. See related article by Apfelbaum et al., p. 4466.

Keyphrases

transcription factor
poor prognosis
single cell
stem cells
binding protein
bone marrow
cell therapy
induced apoptosis
public health
cell cycle arrest
long non coding rna
cell death